What is this document and who is it for?

Similar documents
Annex 2 A. Regional profile: West Africa

Global reductions in measles mortality and the risk of measles resurgence

TT Procured by UNICEF

Eligibility List 2018

The Promise of Introducing Rubella Containing Vaccines on the Impact of Rubella and Measles Control

COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)

Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division

PROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA

1) SO1: We would like to suggest that the indicator used to measure vaccine hesitancy be DTP 1 to measles first dose dropout.

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

AIDS in Africa. An Update. Basil Reekie

Malaria Funding. Richard W. Steketee MACEPA, PATH. April World Malaria Day 2010, Seattle WA

Rotavirus Vaccine: Supply & Demand Update. UNICEF Supply Division

IMMUNIZATION & VACCINE PREVENTABLE DISEASES

Prioritizing Emergency Polio Eradication Activities

Comparative Analyses of Adolescent Nutrition Indicators

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

APPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

Update from GAVI Aurelia Nguyen

EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT

Disparities in access: renewed focus on the underserved. Rick Johnston, WHO UNC Water and Health, Chapel Hill 13 October, 2014

Financing malaria control

MEASLES ELIMINATION BY 2020: A STRATEGY FOR THE AFRICAN REGION. Report of the Secretariat. Executive Summary

BCG. and your baby. Immunisation. Protecting babies against TB. the safest way to protect your child

Sourcing of ARVs & HIV diagnostics. Procurement for Impact P4i

מדינת ישראל. Tourist Visa Table

IMMUNIZATION VACCINES & EMERGENCIES

HPV Vaccine Lessons Learned & New Ways Forward

Global Fund Results Fact Sheet Mid-2011

Scaling Up Nutrition Action for Africa

מדינת ישראל. Tourist Visa Table. Tourist visa exemption is applied to national and official passports only, and not to other travel documents.

Aboubacar Kampo Chief of Health UNICEF Nigeria

Review of decisions Debbie Adams

POLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12

World Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts

Funding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia

Measles Supplementary Immunization Activities and GAVI Funds as Catalysts for Improving Injection Safety in Africa

Ouagadougou Declaration

Certificate of Immunization

THE CARE WE PROMISE FACTS AND FIGURES 2017

Health systems and HIV: advocacy. Interagency Coalition on AIDS and Development

PROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS

#1 #2 OR Immunity verified by immune titer (please attach report) * No titer needed if proof of two doses of Varicella provided

1. Consent for Treatment This form must be completed in order to receive healthcare services in the campus clinic.

This portion to be completed by the student Return by July 1 Please use ballpoint pen

Analysis of Immunization Financing Indicators from the WHO-UNICEF Joint Reporting Form (JRF),

Global Fund ARV Fact Sheet 1 st June, 2009

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved

JOINT TB AND HIV PROGRAMMING

TFI Proceedings, Recommendations and implications for 2005

Wild Poliovirus*, 03 Aug 2004 to 02 Aug 2005

NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL. Measles & Rubella Campaigns

Global Fund Mid-2013 Results

FRAMEWORK FOR IMPLEMENTING THE GLOBAL STRATEGY TO ELIMINATE YELLOW FEVER EPIDEMICS (EYE), IN THE AFRICAN REGION. Report of the Secretariat

Challenges and Opportunities to Optimizing the HIV Care Continuum Can We Test and Treat Enough People to Make a Seismic Difference by 2030?

Maternal Deaths Disproportionately High in Developing Countries

Private Sector Opportunities to Support Family Planning and Access to Reproductive Health Services

Global Polio Eradication Initiative

! Multisectoral Information, Data, Research & Evidence - for Health, Population, Human & Social Development!

What is Treatment Optimisation (TO)

POLIO ERADICATION IN THE AFRICAN REGION: PROGRESS REPORT. Information document EXECUTIVE SUMMARY

STUDENT HEALTH SERVICES NEW STUDENT QUESTIONNAIRE

Donor Support for Contraceptives and Condoms for STI/HIV Prevention

Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries

FP2020 Expert Advisory Community Webinar

VIEW-hub Report: Global Vaccine Introduction and Implementation

FORMS MUST BE COMPLETED PRIOR TO THE START OF YOUR FIRST SEMESTER

Outcomes of the Global Consultation Interim diagnostic algorithms and Operational considerations

IMMUNIZATION VACCINE DEVELOPMENT

Sexual and reproductive health care: A comparison of providers and delivery points between the African Region and other regions

Yellow fever Vaccine investment strategy

ANNEX 3: Country progress indicators

Development of the Polio Eradication and Endgame Strategic plan

Africa s slow fertility transition

Overview of WHO/UNICEF Immunization Coverage Estimates

Update on Progress and Challenges in Achieving Measles and Rubella Targets

ASLM Anti-microbial Resistance in Africa and Global Health Security. 9TH INTEREST WORKSHOP May 2015 Harare

AFRICA. The continent of All challenges

Performance of National Measles Case-Based Surveillance Systems in The WHO African Region

Pharmacovigilance BMGF Perspective. Raj Long Bill & Melinda Gates Foundation

UNAIDS 2013 AIDS by the numbers

Progress has been made with respect to health conditions.

GABON. Neglected tropical disease treatment report profile for mass treatment of NTDs

O c t o b e r 1 0,

UNDERGRADUATE STUDENT HEALTH PACKET

Global Measles and Rubella Update. April 2018

Tipping the dependency

Gavi s strategic framework 22 June 2016

WHO report highlights violence against women as a global health problem of epidemic proportions

ONLINE APPENDIX. The Lives Saved Tool (LiST) (Version 4.2 Beta 7) was used to. project the number of child deaths that would be averted between

Expert Group Meeting on the Regional Report for the African Gender and Development Index

Foot-and-Mouth Disease Situation Food and Agriculture Organization of the United Nations Monthly Report

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

STUDENT MEDICAL REPORT For Graduate and Part-time Undergraduate Students The State of Connecticut General Statutes Section 10a and Fairfield

IMMUNIZATION VACCINE DEVELOPMENT

Closing the loop: translating evidence into enhanced strategies to reduce maternal mortality

The Immunization Record is available to download from the Health Insurance and Immunizations website at drexel.edu/hii/forms.

D TA companion & Scorecard. to the UNICEF Gender Action Plan. May 2016

Transcription:

Measles and Rubella Initiative s Standard Operating Procedures for Accessing Support for Measles and Rubella Supplementary Immunization Activities During 2016 In the context of measles and rubella elimination and control, country programs conduct periodic supplemental immunisation activities (SIAs) to reduce the size of susceptible populations. To achieve population immunity necessary for the interruption of measles transmission, a measles stand-alone or measles-rubella combined campaign must reach at least 95 per cent of a target population. What is this document and who is it for? This document is intended to provide managers of immunization programs in eligible countries with guidance on how to access Measles & Rubella Initiative (M&RI) support for quality SIAs during 2016. It outlines a set of Standard Operating Procedures (SOPs) for accessing financial and/or technical support through the M&RI. Separate SOP s must be used to apply for emergency outbreak response that are available at http://www.measlesrubellainitiative.org/wp- content/uploads/2013/06/sop- Funding-Request.pdf In 2017 Gavi, the Vaccine Alliance will implement a new strategy for financing measles and measlesrubella SIAs using Gavi funds. These M&RI SOPs will be revised for 2017 based on the implementation of this strategy by the Gavi Secretariat. The experience of the M&RI is that early preparations, timely arrival of funds to the periphery and supervision are the key insurance against poor quality SIAs. It is hence critical that countries seeking M&RI support adhere to strict timelines and follow the guidance outlined in these SOPs. Late or incomplete country submissions negatively impact on M&RI support and reduce the efficacy of SIAs in closing immunity gaps. What is the Measles & Rubella Initiative? The Measles & Rubella Initiative is a global partnership founded in 2001 by the American Red Cross, the United States Centers for Disease Control and Prevention (CDC), the United Nations Foundation (UNF), the United Nations Children s Fund (UNICEF), and the World Health Organization (WHO). It is committed to ensuring that no child dies from measles or is born with congenital rubella syndrome (CRS). Working with Ministries of Health, donor governments, the private sector, and civil society, the M&RI provides technical and financial assistance to enable countries to achieve the Global Vaccine Action Plan (GVAP) goals, which are committed to the elimination of measles and rubella in at least five of the six WHO regions by 2020. How does the M&RI support a country? The M&RI and its partners provide eligible priority countries (see below) with a wide range of financial and technical support. This includes support for SIAs, routine immunization strengthening through SIA s, post-sia surveys, and surveillance. Financial support: SIA campaign costing: based on over 10 years of experience and UNICEF Supply Division procurement, M&RI uses the following average base calculators per child to be vaccinated as of 2016: Measles Measles +Rubella Bundled Vaccine (incl. injection devices, safety boxes) + Freight $0.41 $0.80 Operational costs (incl. logistics, social mobilization etc.) $0.94 $0.94 Total $1.35 $1.74

If approved, M&RI provides a country with bundled vaccine costs plus up to 50% of a SIAs operational costs. The recipient country is obligated to finance the balance of the operational costs with government funds or in-country partner funding. Technical assistance: The M&RI has accumulated a wealth of experience and provides qualified technical expertise mainly through WHO, UNICEF and CDC. When a country requires additional surge capacity for SIAs, M&RI can mobilize experts to support government and in-country partners in overall coordination, microplanning and preparations and guiding course adjustments in logistics, communications, vaccine and cold-chain management, injection safety and cascade training. The deployment of technical support is determined on a case by case basis according to a country request. Which countries are eligible for M&RI support? Countries generally eligible for M&RI funding for SIAs and/or technical assistance are the 77 focus countries below: T he M&RI 77 focus Countr ies, by WHO Region: Africa Region: Angola, Botswana, Burundi, Comoros, Eritrea, Ethiopia, Kenya, Lesotho, Madagascar, Malawi, Mozambique, Namibia, Rwanda, South Africa, South Sudan, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe. Algeria, Benin, Burkina Faso, Cape Verde, Cote d Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, and Togo. Cameroon, Central African Republic, Chad, Congo Brazzaville, Congo DR, Equatorial Guinea, Gabon, and Sao Tome and Principe South-East Asia Region: Bangladesh, India, Indonesia, Korea DRP, Myanmar, Nepal, and Timor Leste Western Pacific Region: Cambodia, Kiribati, Laos, Micronesia, Papua New Guinea, the Philippines, Samoa, Solomon Islands, Tuvalu, Vanuatu, and Viet Nam Eastern Mediterranean Region: Afghanistan, Djibouti, Iraq, Lebanon, Pakistan, Somalia, Sudan, Syria, and Yemen. Region of the Americas: Bolivia, Dominican Republic, and Haiti Other countries not on this list interested in conducting a measles or MR SIA may apply for M&RI support. This request will be discussed with UNICEF and WHO RO and CO for justification and prioritization. Final decisions on support and the amount will be made by the M&RI Management Team, based on funds available. Recommended timeline of activities and steps; application and approval process In the last quarter of each year, WHO and UNICEF will prepare a funding request that includes current information on countries planning or expected to conduct SIAs in the following year. National program managers should keep their WHO and UNICEF country offices informed of their SIA plans in

a continuous manner, and provide a plan of action at least 12 months before a scheduled campaign. For example, if a country is scheduling a campaign in March 2017 with M&RI support, the plan of action should sent in the March of 2016. The timeline below summarizes the key steps in accessing M&RI support for SIAs:

Recommended steps, timeline, application and approval processes in accessing M&RI support for SIAs Obtain government commitment to raise at least 50% of the SIA s operational costs from government resources and/or local partners. Provide the following documents by 12 months before SIA start: 1. A formal Funding Request (Annex 2) 2. An SIA Plan of Action (POA) with a budget (Annex 3) endorsed by a country s Inter- Agency Coordinating Committee (ICC) or a similar national-level coordinating body. Review by the M&RI Submit vaccine and devices request to UNICEF Implementation Year -17-18 m -16 m -15 m -14 m -13 m -12 m -9 m -8 m -7m -6 m 4 6 months SIA implemen tation 1 month post SIA 2 months Post campaign Planning Year Summary: Decision by M&RI. Decision is formally relayed to the country Min of Health. WHO and UNICEF transfer funds for operational costs to country and for bundled vaccine to UNICEF Supply Division Country prepares & monitors progress using the WHO SIAs readiness assessment tool Conducts SIAs 1. Programme should ensure national budget includes request for 50% of SIA costs during the planning year. 2. The funding request (Annex 1) and Plan of Action should be submitted to M&RI at least 12 months before the planned start of the SIA. 3. It is critical that requests for vaccines and injection devices are submitted 6 months before the planned launch date of the SIAs. 4. Post-SIA technical report should be sent with the administrative coverage data within 2 months after the close of the SIA. Country conducts coverage survey & evaluation Country submits official report to the M&RI

Annex 1. M&RI Funding Request 1. Interventions planned to be given during the SIA, beginning with M or MR vaccine but also including all other interventions planned, with target age range and estimated target population: Intervention Target age range Target population 2. Objectives: 3. Implementing organization: 4. Partners: 5. Budget (US$): Total needed Govt. M&RI Specify partner & amounts Specify partner & amounts Bundled vaccine Other interventions Operations Routine strengthening Post-SIA coverage survey Total Budget Measles/ Measles- Rubella (MR) vaccine and devices requirements (UNICEF to forward to Supply Division) Target Population Date of the Campaign Description Unit Wastage factor Quantity Date of expected delivery Measles vaccine Doses AD syringes+ needles Pieces RUP Pieces Safety boxes Pieces

Annex 2. Suggested Outline for a Country Plan of Action This outline gives the basic elements required for a Plan of Action submitted to the M&RI for SIAs support 1. Executive Summary 2. Context a. History of routine immunization and SIAs with measles or MR vaccine, including dates of introduction of MCV1, MCV2, and MR. b. Surveillance data for measles (and rubella if appropriate) with knowledge of outbreak affected areas c. Justification for the current SIAs d. Lessons learned from previous SIAs 3. Objectives, targets for the campaign 4. Other planned integrated interventions 5. Linkages to other activities planned during the year 6. Planning and implementation a. SIA task forces and sub-commissions or sub-committees b. Cold chain and logistics, including current inventory of total and available cold chain capacity c. Vaccination strategies d. Communications and social mobilization e. Strengthening / supporting routine immunization through the campaign f. Injection safety and waste management g. Adverse event reporting, management and communications 7. Monitoring and evaluation a. Indicators, objectives for each indicator, and how they will be measured b. Pre-campaign monitoring of readiness and response actions c. During the campaign: monitoring of doses delivered and rapid convenience monitoring to find missed children d. Post-campaign coverage survey 8. Costing and financing 9. Partners roles in implementation and finance 10. Timeline of activities for SIAs (Table) 11. Timeline of planning and implementing coverage survey (Table)